Search Within

Sujana Movva

Formats
  1. Meeting Abstract (26)
  2. Journal Article (21)
  3. Correspondence (1)
Groups
  1. Department of Medicine (48)
  2. Sarcoma Service (48)
  3. Solid Tumor Oncology Division (48)
  4. GSK Faculty (38)
  5. Tow Center for Developmental Oncology (TCDO) (38)
  6. Hematologic Malignancies, Division of (36)

More Groups

People
  1. Ciara Kelly (38)
  2. Sandra D'Angelo (36)
  3. William Tap (36)
  4. Mark Dickson (35)
  5. Mary Keohan (35)
  6. Ping Chi (35)

More People

Years
  1. 2025 (2)
  2. 2024 (13)
  3. 2023 (9)
  4. 2022 (14)
  5. 2021 (2)
  6. 2020 (7)

More Years

Publications
  1. Journal of Clinical Oncology (19)
  2. Clinical Cancer Research (11)
  3. Annals of Oncology (5)
  4. JCO Precision Oncology (2)
  5. Journal for ImmunoTherapy of Cancer (2)
  6. Nature Communications (2)

More Publications

Publishers
  1. American Society of Clinical Oncology (21)
  2. American Association for Cancer Research (12)
  3. Oxford University Press (6)
  4. Biomed Central Ltd (2)
  5. Nature Publishing Group (2)
  6. American Medical Association (1)

More Publishers

Results (48)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Safety and clinical activity of TTI-621 in combination with doxorubicin in patients with unresectable or metastatic high-grade leiomyosarcoma: Results from the low-dose expansion cohort
    Meeting Abstract

    Movva, S.; Druta, M.; Davis, L. E.; Monga, V.; Milhem, M. M.; Bailey, H. H.; Chugh, R.; Bruns, I.; Allgood, V. E.; Chawla, S. P.
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, Ciara M.; Keohan, M. L.; Meyers, P. A.; Cohen, S. M.; Hensley, M. L.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Interim results of a phase II trial of first line retifanlimab (R) plus gemcitabine and docetaxel (GD) in patients (pts) with advanced soft tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Dickson, M. A.; Keohan, M. L.; Gounder, M. M.; Chi, P.; Movva, S.; Kelly, C. M.; Avutu, V.; Chan, J. E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase II study of epacadostat and pembrolizumab in patients with advanced sarcoma
    Journal Article

    Kelly, C. M.; Qin, L. X.; Whiting, K. A.; Richards, A. L.; Avutu, V.; Chan, J. E.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
    Meeting Abstract

    Nacev, B. A.; Sanchez-Vega, F.; Smith, S.; Antonescu, C.; Rosenbaum, E.; Shi, H.; Tang, C.; Socci, N.; Rana, S.; Gularte-Merida, R.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I/II trial of the PD-1 inhibitor retifanlimab (R) in combination with gemcitabine and docetaxel (GD) as first-line therapy in patients (Pts) with advanced soft-tissue sarcoma (STS)
    Meeting Abstract

    Rosenbaum, E.; Qin, L. X.; Thornton, K. A.; Movva, S.; Nacev, B. A.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Avutu, V.; Chi, P.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • A pilot study of lenvatinib plus pembrolizumab in patients with advanced sarcoma
    Meeting Abstract

    Movva, S.; Avutu, V.; Chi, P.; Dickson, M. A.; Gounder, M. M.; Kelly, C. M.; Keohan, M. L.; Nacev, B. A.; Rosenbaum, E.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Presence of immune infiltrates, increased expression of transposable elements, and viral response pathways in sarcoma associate with response to checkpoint inhibition
    Meeting Abstract

    Nacev, B. A.; Bradic, M.; Richards, A. L.; Kelly, C. M.; Dickson, M. A.; Gounder, M. M.; Keohan, M. L.; Chi, P.; Movva, S.; Thornton, K. A.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Surufatinib in US patients with soft tissue sarcoma
    Meeting Abstract

    Movva, S.; Spira, A. I.; Hamilton, E. P.; Wang, J. S.; Cohn, A. L.; Strauss, J. F.; Stacchiotti, S.; Tucci, C.; Kauh, J.; Nanda, S.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save
  • Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors
    Meeting Abstract

    McKean, M.; Tolcher, A. W.; Reeves, J. A.; Chmielowski, B.; Shaheen, M. F.; Beck, J. T.; Orloff, M. M.; Somaiah, N.; Van Tine, B. A.; Drabick, J. J.; more...
    Journal of Clinical Oncology (2022)

    Fulltext@MSK | Save